Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Pharmacology of endocrine disorders - hormones of thyroid gland, thyreostatics Jan Bultas, P. Potměšil [email protected] 2013 Thyroid and anti-thyroid drugs A/ THYROID THERAPEUTICS B / anti-THYROID THERAPEUTICS I. hormones I. derivatives of thiourea 1/ levothyroxin, 1/ carbimazol 2/ thiamazol (= methimazol) 3/ propylthiouracil or combination: levothyroxin+liothyronin II. drugs with iodine (2/ liothyronin) II. drugs with iodine 1/ kalii iodidum = kalium iodatum 1/ kalium iodatum thyreostatic eff. if applied >6000 microgr/d 2/ radioactive iodine 131I (III. kalii perchloras) (inh. of iodine pump, protection of thyroid gl. during radionuclide examination) Treatment of diseases of thyroid gland – hormones from thyroid gl. T4 (tyroxin) T3 (trijodthyronin, liothyronin) calcitonin (parafollicular cells) Thyroid hormones thyroxin (T4) trijodthyronin (T3) hypothalamus TRF hypophysis TSH thyroid gl. T4 a T3 Molecular effects of T3 and T4 • genomic effects: - stimulation of nuclear transcription factors (↑ activity DNAdependent RNA-polymerase) and increase of synthesis of new RNA • non-genomic effects - stimulation of many ion channels and enzymes – influencing of nerv. synapt., metabolism of calcium, cell proliferation (e.g. neurons and glial cells in CNS) - influencing of production of ATP (by phosphorylation of ADP) or heat by oxidative phosphorylation on mitochondrial membrane Function of thyroid hormones I. primarily: • regulation of metabolism (oxidative phosphorylation) • regulation of developement of foetal nervous system II. secondary: • potentiation of effect of catecholamines • increase of contractility of myocardium and acceleration of heart rate • increase of gut motility • acceleration of muscle contraction • stimulation of synthesis of bile acids → increase of catabolism of cholesterol with LDL-cholesterol Synthesis of thyroid hormones • uptake of iodine by gl. thyreoidea (Na/I symporter, stimul. by TSH) • binding of iodine to thyreoglobulin • storage of tyreoglob. with mono- a di-iodtyrosine residues (MIT / DIT) in follicles • synthesis of T4 and T3 from MIT / DIT (very low turnover, huge stock) • release of T4 and T3 to plasma (proteolysis of thyreoglobulin) • conversion of T4 to T3 in tissues • degradation of T3 Synthesis of thyroid hormons Iodization of tyreoglobuline reabsorption tyreoglob. Oxidation of iodine Synthesis of tyreoglob. Release of T4 and T3 Uptake of iodine Release of T4 and T3 Synthesis of thyroid hormons Secretion of T4 and T3 • stimulation of hypothalamus (cold, stress) TRH (tyrotropin releasing hormone) TSH • TSH - iodine uptake - synthesis and secretion of thyroglobulin - synthesis of T3, T4 - hydrolysis tyreoglob. secretion of T3 and T4 • inhibition of TSH by negative feedback T3 > T4 • secretion of T3 and T4 is inhibited by lithium Transport of T4 and T3 type % Binding to thyroxine-binding globulin (TBG) 70% Binding to transthyretin (pre-albumin) and para-albumin 30% Non bound T4 (fT4) 0,03% Non bound T3 (fT3) 0,3% risk of displacement from binding to plasm. proteins free T4 is present in much lower concentr. – main eff. is mediated by T3 Thyroxin and trijodtyronin T4 - main circulating hormon (98.5% T4, 1.5% T3) - bound to proteins (TBG, albumin), free fraction - only free fraction of T4 and T3 is effective - conversion of T4 to T3 in tissues - long half-life of effect - one week approximately T3 - main effective hormone (about one order more effective) - shorter half life ( day) - binding to proteins, free fraction Thyroxin (levothyroxin - T4) • synthetic - conversion to T3 • the most frequently used dosis during treatment of hypothyreosis 1,6 ug/kg ( of dosis in cardiologic patients and if patient is > 60 yrs) • normalization of TSH is leading info about succesful therapy, control after dosis adjustment after 4-6 wks, high persistence of effect • biochemically all patients are eutyroid, not all patients are eutyroid from the clinical point of view • medicinal products with brand names: Eltroxin, Letrox Trijodtyronin (liotyronin - T3) • shorter duration of effect (1-2x daily) • 10x stronger and faster effect - Adv. eff.: palpitation • applied in combination with thyroxine in pat. with subj. insuff. compensation of hypothyreosis • in majority of patients thyroxine is more advantageous • brand name of medicin. prod.: Thyreotom Information about clinical effect of treatment - laboratory tests • • • • level of TSH in serum [plasma] free (event. total) T4 free T3 … Hypothyreosis - treatment substitution: - thyroxin (levotyroxin) – in majority of patients we can achieve optimal eff., - alternative is to use comb. of thyroxine and triiodtyronine (e.g. 1:4), used for improvement of subj. condition when lab. finding indicate euthyroid function and subj. symptoms of hypothyreosis are present - titration of dosis according to lab. and also biochem. results - most frequently used dose 1.6 g/kg - dose in cardiacs and persons > 60 yrs - brand names of MP are: Eltroxin, Euthyrox, Letrox, Thyreotom,… Treatment of thyreotoxicosis • pharmacotherapy - thionamides (carbimazol, methimazol, propylthiouracyl) - high doses of iodine, -blockers • ablation by radioactive iodine • surgical ablation (subtot. STE) THIONAMIDES - carbimazol, methimazol, propylthiouracyl • derivatives of thiourea • inhibit peroxidase reaction and iodization of tyrosine residues in thyreoglobuline - decrease of synthesis of T4 and T3 • carbimazol conversion to effect. methimazol • propylthiouracyl inhibits in addition conversion of T4 to T3 • proper pharmacodynam. effect is rapid, because of long half-life of T4 clin. effect is apparent after 2-3 wks SE: granulocytopenia, exantema Effect of thyreostatic drugs Iodization of tyreoglob. Reabsorption of tyreoglob. carbimazol propylthiouracyl iod (high doses) oxidation Of iodine tyreoglob. synth. Release of T4 a T3 Uptáke of iodine Conversion of release T4 to T3 of T4 and T3 propylthiouracyl glucocorticoids Strategy of therapy with thyreostatic medicin. products • titrating regimen– we decrease initial dosis of thyreostatic drug according to clin. state and accrding to values of free T3 and T4 - more practical approach • block regime – application of combination of thyreostatic drug (for suppresion of function) and thyroxine for substitution • long-term comparison without clinical difference CAVE: inducers of CYP (rifampicin, phenobarbital, phenytoin) significantly accelerate degradation of T3 and T4 Effect of -blockers during thyreotoxicosis T4 - increases expression of cardial rec. 1 - increases activity of catecholamines palpitation, tachycardia -blockers are advantageous during thyreotoxicosis Radioiodine (isotop 131I) • + emitter (importance only radiation) • cytotoxic effect approximately after 2 months • incorporation to thyreoglobulin • treatment of Graves Basedow disease • do not prescribe to children and gravid women Iodine for treatment of thyreopathy (Lugol solution) • substitutive treatment - low doses • tyreostatic treatment - high doses of iodine suppress release of T4 and T3 by inhibition of iodidation of tyrosine in tyreoglobuline – rapid effect • treatment of tyreotoxic crisis (effect after 24 hrs) • preparement before strumectomia Surgical treatment – subtotální strumektomie before operation: • tyreostatic treatment (avoid release of T4 and T3 and development of tyreotox. crisis) • iodine (decreases vascularization) • risk of hypoparathyreosis and cut of n. phrenicus Treatment of thyreotoxic crisis stabilization of circulation - blockade of rec. 1 reduction of tachycardia and risk of arytmias (bisoprolol, metoprolol,…) - blockade of rec. 2 calming down of tremor (metipranol –Trimepranol) decrease of thyroid function -carbimazol, event. propylthiouracyl - iodine (Lugol), lithium - high doses of glucocorticoids Mortality of crisis reduced from 100% to 20% Strategy of treatment of tyreotoxicosis ablation with radioiodine: GB disease, tox. adenoma - 80-90% eutyroid till 2 months - worsening of oftalmopathy (need to comb. with glucocorticoids) tyroidectomia: GB disease, tox. adenoma, Carc. - 90% eutyroid, does not worsen opthalmopathy - risk of compl. (hypoparathyreosis, n. phrenicus) tyreostatic drugs: GB disease (if adenoma only preparement for STE) - 60% eutyroid after 12-18 months of treatment, does not worsen opthalmopathy, less effective during tox. adenoma